中草药

金振口服液改善慢性阻塞性肺疾病合并痰热证大鼠模型的药效学评价及机制研究

PDF下载

中草药 | 药理与临床 2026,57(9): 3429-3444

收起

中草药 |药理与临床 2026 , 57 (9) : 3429 -3444

金振口服液改善慢性阻塞性肺疾病合并痰热证大鼠模型的药效学评价及机制研究

全屏

胡梦雨¹, 杨钰冰¹, 施祎琳¹, 郭士铎¹, 杨婉婷¹, 张新庄¹, 曹亮¹, 肖伟¹, 武子寅¹, 王振中¹

作者信息

通讯作者:

武子寅

作者简介:

胡梦雨: 胡梦雨(2001-),女,硕士研究生,研究方向为中药制剂技术与产品开发。E-mail:18651678026@163.com

Pharmacodynamic evaluation and mechanistic study of Jinzhen Oral Liquid in rats with chronic obstructive pulmonary disease complicated by phlegm-heat syndrome

HU Mengyu, YANG Yubing, SHI Yiling, GUO Shiduo, YANG Wanting, ZHANG Xinzhuang, CAO Liang, XIAO Wei, WU Ziyin, WANG Zhenzhong

Affiliations

doi: 10.7501/j.issn.0253-2670.2026.09.015

文章导航

摘要

收起

目的系统评估金振口服液（Jinzhen Oral Liquid，JZOL）对慢性阻塞性肺疾病（chronic obstructive pulmonary disease，COPD）合并痰热证病理模型的治疗作用，并从肺功能改善、全身炎症抑制、气道黏液分泌调节、Th1/Th2和Th17/Treg免疫平衡恢复以及转录组表达谱调控等维度，阐明其药理作用机制。方法采用香烟烟雾联合脂多糖（lipopolysaccharide，LPS）鼻腔滴注的方式，持续8周建立大鼠COPD模型；随后通过风热暴露联合LPS滴注9 d，构建COPD合并痰热证复合模型。将模型大鼠随机分为模型组、地塞米松（0.2 mg/kg）组和JZOL低、中、高剂量（0.8、1.6、3.2 g/kg）组，连续给药7 d。通过检测肺功能指标、全身症状及体征、血清炎症因子、肺组织病理以及肺组织T细胞亚群比例，综合评价JZOL的药效；进一步采用转录组测序及qRT-PCR技术，验证JZOL对脂质运载蛋白2（lipocalin 2，Lcn2）、吲哚胺2,3-双加氧酶1（indoleamine 2,3-dioxygenase 1，Ido1）、细胞周期蛋白E1（cyclin E1，Ccne1）、同源框B8（homeobox protein B8，HoxB8）、G蛋白偶联受体17（G protein-coupled receptor 17，Gpr17）等关键差异基因的调控作用。结果复合造模成功诱导了大鼠严重的气流受限、发热、便秘症状，以及组织和细胞病理学变化。与模型组比较，JZOL显著改善肺功能（P＜0.05、0.01、0.001），显著降低血清中肿瘤坏死因子-α（tumor necrosis factor-α，TNF-α）、白细胞介素-6（interleukin-6，IL-6）、C反应蛋白（C-reactive protein，CRP）和中性粒细胞弹性蛋白酶（neutrophil elastase，NE）水平（P＜0.001），显著减轻支气管上皮杯状细胞增生及酸性黏蛋白分泌（P＜0.05、0.001），并纠正失衡的Th1/Th2和Th17/Treg细胞比例（P＜0.05、0.001）。转录组及qRT-PCR验证结果显示，JZOL通过下调免疫微环境与蛋白酶失衡相关基因、抑制异常细胞周期与气道重塑基因、上调肺再生关键因子并调节发育因子，以及激活组织修复与炎症消退路径等多途径机制改善COPD。结论 JZOL通过多靶点抑制全身及局部炎症反应、调节T细胞免疫平衡，从而有效改善COPD合并痰热证大鼠的肺功能及全身症状。

关键词

慢性阻塞性肺疾病 / 金振口服液 / 痰热证 / 炎症 / 免疫调节 / 转录组测序

Abstract

收起

Objective To systematically evaluate the therapeutic effects of Jinzhen Oral Liquid (金振口服液, JZOL) on a pathological model of chronic obstructive pulmonary disease (COPD) complicated with phlegm-heat syndrome, and to elucidate its pharmacological mechanisms from multiple dimensions, including improvement of pulmonary function, suppression of systemic inflammation, regulation of airway mucus secretion, restoration of Th1/Th2 and Th17/Treg immune balance, and modulation of transcriptomic expression profiles. Methods A rat COPD model was established through eight weeks of cigarette smoke exposure combined with intranasal lipopolysaccharide (LPS) instillation. Subsequently, a compound model of COPD with phlegm-heat syndrome was induced by 9 d of wind-heat exposure combined with LPS instillation. Model rats were randomly assigned to model group, dexamethasone (0.2 mg/kg) group and JZOL low-, medium-, high-dose (0.8, 1.6, 3.2 g/kg) groups, and received continuous oral administration for 7 d. Therapeutic efficacy was comprehensively evaluated by assessing pulmonary function parameters, systemic symptoms and signs, inflammatory factors in serum, lung histopathological changes and proportions of lung T cell subsets in lung tissue. Furthermore, transcriptomic sequencing and qRT-PCR were employed to validate the regulatory effects of JZOL on key differentially expressed genes, including lipocalin-2 (Lcn2), indoleamine 2,3-dioxygenase 1 (Ido1), cyclin E1 (Ccne1), homeobox protein B8 (Hoxb8) and G protein-coupled receptor 17 (Gpr17). Results The compound modeling successfully induced severe airflow limitation, fever, constipation, and histopathological and cytopathological alterations in rats. Compared with model group, JZOL significantly improved lung function (P < 0.05, 0.01, 0.001), significantly reduced levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), C-reactive protein (CRP) and neutrophil elastase (NE) in serum (P < 0.001), significantly reduced bronchial epithelial goblet cell proliferation and acid mucin secretion (P < 0.05, 0.001), and corrected imbalanced Th1/Th2 and Th17/Treg cells ratios (P < 0.05, 0.001). The transcriptome and qRT-PCR validation results showed that JZOL improved COPD through multiple mechanisms, including downregulation of immune microenvironment and protease imbalance related genes, inhibition of abnormal cell cycle and airway remodeling genes, upregulation of key lung regeneration factors and regulation of developmental factors, as well as activation of tissue repair and inflammation resolution pathways. Conclusion JZOL effectively improves lung function and systemic symptoms in COPD rats with phlegm heat syndrome by inhibiting systemic and local inflammatory responses through multiple targets, regulating T cell immune balance.

Key words

chronic obstructive pulmonary disease / Jinzhen Oral Liquid / phlegm-heat syndrome / inflammation / immunomodulation / transcriptome sequencing

引用本文

胡梦雨, 杨钰冰, 施祎琳, 郭士铎, 杨婉婷, 张新庄, 曹亮, 肖伟, 武子寅, 王振中. 金振口服液改善慢性阻塞性肺疾病合并痰热证大鼠模型的药效学评价及机制研究. 中草药, 2026 , 57 (9) : 3429 -3444 . DOI: 10.7501/j.issn.0253-2670.2026.09.015

HU Mengyu, YANG Yubing, SHI Yiling, GUO Shiduo, YANG Wanting, ZHANG Xinzhuang, CAO Liang, XIAO Wei, WU Ziyin, WANG Zhenzhong. Pharmacodynamic evaluation and mechanistic study of Jinzhen Oral Liquid in rats with chronic obstructive pulmonary disease complicated by phlegm-heat syndrome[J]. Chinese Traditional and Herbal Drugs, 2026 , 57 (9) : 3429 -3444 . DOI: 10.7501/j.issn.0253-2670.2026.09.015

基金

收起

湖北省科技厅重点研发项目(2025BCB067);宜昌市医疗卫生研究项目(A22-2-059,A23-1-066);湖北省科技厅重点研发大健康计划项目(2022BCE017);湖北省卫生健康委员会中医药重点项目(ZY2023Z015);湖北省卫生健康委员会中医药面上项目(ZY2025M038);湖北省科技厅自然科学基金项目(2025AFB805,2025AFB839,2025AFD301,2025AFD294,2023AFB600,2022CFB357,2022CFB427);湖北省卫生健康委员会科研资助项目(WJ2023M153);湖北省功能性消化系统疾病中医临床医学研究中心开放基金项目(SXZ202303,SXZ202308,SXZ202311)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

GBD 2015 Chronic Respiratory Disease Collaborators.Global, regional, and national deaths, prevalence,disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015:A systematic analysis for the Global Burden of Disease Study 2015[J]. Lancet Respir Med,2017, 5(9):691-706.
Yin P, Wu J Y, Wang L J, et al. The burden of COPD in China and its provinces:Findings from the global burden of disease study 2019[J]. Front Public Health, 2022, 10:859499.
Li J Y, Ye Z G. The potential role and regulatory mechanisms of MUC5AC in chronic obstructive pulmonary disease[J]. Molecules, 2020, 25(19):4437.
Zhang H L, Si Y M, Du Y, et al. Exploration of biomarkers for efficacy evaluation of traditional Chinese medicine syndromes of acute exacerbation of chronic obstructive pulmonary disease based on metabolomics[J]. Front Pharmacol, 2024, 15:1302950.
Chen Y K, Zhang W B. Zhuye Shigao Decoction combined with Qingqi Huatan Pills in alleviating the acute exacerbation of chronic obstructive pulmonary disease(phlegm-heat stagnating in the lungs)via the IL-6-mediated JAK1/STAT3 signaling pathway[J]. Evid Based Complement Alternat Med, 2022, 2022:7942623.
张真,伊明洋,李伟珂,等.从基础证探讨中药复方治疗慢性阻塞性肺疾病急性加重的用药规律及分子调控机制[J].中草药, 2025, 56(17):6278-6300.
Tian P W, Wen F Q. Clinical significance of airway mucus hypersecretion in chronic obstructive pulmonary disease[J]. J Transl Int Med, 2015, 3(3):89-92.
Voynow J A, Shinbashi M. Neutrophil elastase and chronic lung disease[J]. Biomolecules, 2021, 11(8):1065.
ŠileikienėV, JurgauskienėL. Role of regulatory T cells in pulmonary ageing and COPD development[J]. Int J Mol Sci, 2025, 26(8):3721.
AgustíA, Celli B R, Criner G J, et al. Global initiative for chronic obstructive lung disease 2023 report:GOLD executive summary[J]. Arch De Bronconeumología, 2023,59(4):232-248.
Shah B K, Singh B, Wang Y K, et al. Mucus hypersecretion in chronic obstructive pulmonary disease and its treatment[J]. Mediat Inflamm, 2023, 2023(1):8840594.
Cagle S D, Landrum L S, Kennedy A M. Chronic obstructive pulmonary disease:Diagnosis and management[J]. Am Fam Physician, 2023, 107(6):604-612.
Pitre T, Lupas D, Mah J, et al. Biologic therapies for chronic obstructive pulmonary disease:A systematic review and network meta-analysis of randomized controlled trials[J]. COPD J Chronic Obstr Pulm Dis,2025, 22(1):2449889.
Fan Q H, Wu C M, Du Y W, et al. Comparison of Jinzhen Oral Liquid and ambroxol hydrochloride and clenbuterol hydrochloride oral solution in the treatment of acute bronchitis in children:A multicenter, non-inferiority,prospective, randomized controlled trial[J]. Acta Pharm Sin B, 2024, 14(12):5186-5200.
Feng J, Gao X, Chen X L, et al. Mechanism of Jinzhen Oral Liquid against influenza-induced lung injury based on metabonomics and gut microbiome[J]. J Ethnopharmacol,2023, 303:115977.
Cui X, Liang L, Geng H J, et al. Efficacy, safety and mechanism of Jinzhen Oral Liquid in the treatment of acute bronchitis in children:A randomized, double-blind,multicenter clinical trial protocol[J]. Front Pharmacol,2022, 13:948236.
Guo J Y, Wang D M, Wang M J, et al. Systematically characterize the substance basis of Jinzhen Oral Liquid and their pharmacological mechanism using UPLC-QTOF/MS combined with network pharmacology analysis[J]. J Food Drug Anal, 2019, 27(3):793-804.
Liu L X, Li H B, Zhang J Y, et al. Quality markers screening of traditional Chinese medicine prescriptions based on the multi-factor analysis strategy:Jin-Zhen Oral Liquid as a case[J]. Arab J Chem, 2024, 17(1):105433.
Upadhyay P, Wu C W, Pham A, et al. Animal models and mechanisms of tobacco smoke-induced chronic obstructive pulmonary disease(COPD)[J]. J Toxicol Environ Health Part B, 2023, 26(5):275-305.
邢小香,付子坚,赵鹏,等.基于代谢组学研究通塞颗粒治疗AECOPD痰热证大鼠机制[J].时珍国医国药,2024, 35(7):1587-1594.
李嘉萌,杨容芳,余丰君,等.不同工艺的芪蛭益肺颗粒对COPD模型大鼠的药效学对比研究[J].世界科学技术-中医药现代化, 2019, 21(11):2428-2435.
Jakimiuk K, Gesek J, Atanasov A G, et al. Flavonoids as inhibitors of human neutrophil elastase[J]. J Enzyme Inhib Med Chem, 2021, 36(1):1016-1028.
Liu L P, Wu Q, Chen Y P, et al. Updated pharmacological effects, molecular mechanisms, and therapeutic potential of natural product geniposide[J]. Molecules, 2022, 27(10):3319.
沈莹,孙海峰.平贝母化学成分及药理作用研究进展[J].化学工程师, 2018, 32(6):62-66.
Zhang C, Zhang Y K, Zhang S N, et al. Intracellular autoactivation of TMPRSS11A, an airway epithelial transmembrane serine protease[J]. J Biol Chem, 2020,295(36):12686-12696.
van den Berge M, Steiling K, Timens W, et al. Airway gene expression in COPD is dynamic with inhaled corticosteroid treatment and reflects biological pathways associated with disease activity[J]. Thorax, 2014, 69(1):14-23.
Lourenço J D, Ito J T, de Arruda Martins M, et al.Th17/Treg imbalance in chronic obstructive pulmonary disease:Clinical and experimental evidence[J]. Front Immunol, 2021, 12:804919.
Zeng S Y, Zhang Y Q, Li S R, et al. From metabolic alterations to chronic inflammation:Mechanisms and immunoregulation of metabolic reprogramming in COPD[J]. Front Immunol, 2025, 16:1698832.
Liu L L, Zhou M, Sun S W, et al. Developmental immune network of airway lymphocytes and innate immune cells in patients with stable COPD[J]. Front Immunol, 2025, 16:1614655.
Van Deren D A, De S, Xu B, et al. Defining the Hoxb8 cell lineage during murine definitive hematopoiesis[J].Development, 2022, 149(8):dev200200.
Fumagalli M, Daniele S, Lecca D, et al. Phenotypic changes, signaling pathway, and functional correlates of GPR17-expressing neural precursor cells during oligodendrocyte differentiation[J]. J Biol Chem, 2011,286(12):10593-10604.
Maekawa A, Xing W, Austen K F, et al. GPR17 regulates immune pulmonary inflammation induced by house dust mites[J]. J Immunol, 2010, 185(3):1846-1854.
Hackett T L, Osei E T. Modeling extracellular matrix-cell interactions in lung repair and chronic disease[J]. Cells,2021, 10(8):2145.
Pinezich M R, Tamargo M A, Fleischer S, et al.Pathological remodeling of distal lung matrix in end-stage cystic fibrosis patients[J]. J Cyst Fibros, 2022, 21(6):1027-1035.

2026年第57卷第9期

PDF下载

引用本文

BibTeX

文章信息

doi: 10.7501/j.issn.0253-2670.2026.09.015

接收时间：2026-01-26
首发时间：2026-09-09

补充材料

相关文章

文章信息

作者

出版历史

收稿日期：2026-01-26

基金

作者信息

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zcy/CN/10.7501/j.issn.0253-2670.2026.09.015

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT